Related Experiment Video
Updated: Aug 19, 2026

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
Published on: November 25, 2014
Recent advances in CB1 cannabinoid receptor antagonists
1Solvay Pharmaceuticals, Research Laboratories, CJ van Houtenlaan 36, 1381 CP, Weesp, the Netherlands. jos.lange@solvay.com
Abstract:
Cannabinoid CB1 receptor antagonists are currently the subject of intensive research due to their highly promising therapeutic prospects. Novel chemical entities having CB1 antagonistic properties have recently been disclosed by several pharmaceutical companies and some academic research groups, some of which are close structural analogs of the leading compound rimonabant (SR-141716A; Sanofi-Synthélabo). A considerable number of these CB1 antagonists are bioisosteres that are derived from rimonabant by the replacement of the pyrazole moiety with an alternative heterocycle. As well as these achiral compounds, Solvay Pharmaceuticals have disclosed a novel class of chiral pyrazolines that are potent and CB1/CB2 subtype-selective cannabinoid receptor antagonists, in which the interactions with the CB1 receptor are highly stereoselective.
Related Concept Videos
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Antipsychotic Drugs: Typical and Atypical Agents
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...

